A Cross-Sectional Study of the Prevalence of Cardiovascular Disease in Adults with Type 2 Diabetes in Turkiye: The CAPTURE Study

dc.contributor.authorBayram, Fahri
dc.contributor.authorBayraktaroglu, Taner
dc.contributor.authorSargın, Mehmet
dc.contributor.authorSahin, Ibrahim
dc.contributor.authorGuldiken, Sibel
dc.contributor.authorDalbeler, Aysegul
dc.contributor.authorSonmez, Alper
dc.date.accessioned2025-05-10T19:53:24Z
dc.date.issued2022
dc.departmentİstanbul Medeniyet Üniversitesi
dc.description.abstractObjective: The primary objective of the CAPTURE study was to estimate the prevalence of cardiovascular disease (CVD) in adults with Type 2 diabetes mellitus (T2DM) across 13 countries from 5 continents. Here, we present the findings from Turkiye. Material and Methods: The non-interventional, cross-sectional CAPTURE study (NCT03811288; NCT03786406) was conducted across 15 centers in Turkiye. Standardized demographic and clinical data were collected from adults with T2DM who were treated by primary or specialist care physicians. The prevalences of CVD and its 7 subtypes were estimated. Descriptive statistics were used for data analysis. Results: Amongst the 801 participants (n=200 from primary care, n=601 from specialist care) with T2DM enrolled, 250 had established CVD, an estimated weighted prevalence of 31.2% (28.0-34.4) 95% confidence interval. Atherosclerotic CVD contributed to the majority (85.6%) of the CVD cases. An estimated 24.0% of the Turkiye sample had coronary heart disease (CHD). Heart failure was the second most predominant CVD subtype in Turkiye is correct sample (5.4%), followed by cardiac arrhythmia and conduction abnormalities (4.7%). Sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists with cardiovascular (CV) benefits were prescribed to 17.5% and 0.1% of the patients, respectively. Conclusion: Approximately 30% of participants with T2DM had established CVD in the CAPTURE Turkiye population, comparable to the global pooled prevalence. CHD was the major contributor and encompassed approximately 75% of the CVD cases. The use of glucose-lowering medication with CV benefits was low compared to the global pooled population, which may be due to the lack of reimbursement of these medications in Turkiye.
dc.identifier.doi10.25179/tjem.2021-86803
dc.identifier.endpage12
dc.identifier.issn1301-2193
dc.identifier.issue1
dc.identifier.scopus2-s2.0-85125288682
dc.identifier.scopusqualityQ4
dc.identifier.startpage1
dc.identifier.trdizinid525305
dc.identifier.urihttps://doi.org/10.25179/tjem.2021-86803
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/525305
dc.identifier.urihttps://hdl.handle.net/20.500.14730/12724
dc.identifier.volume26
dc.identifier.wosWOS:000760354400002
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.language.isoen
dc.publisherAves
dc.relation.ispartofTurkish Journal of Endocrinology and Metabolism
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250302
dc.subjectCross-sectional study
dc.subjectprevalence
dc.subjectcardiovascular disease
dc.subjectType 2 diabetes mellitus
dc.subjectTurkiye
dc.titleA Cross-Sectional Study of the Prevalence of Cardiovascular Disease in Adults with Type 2 Diabetes in Turkiye: The CAPTURE Study
dc.typeArticle

Dosyalar

Orijinal paket

Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
12724.pdf
Boyut:
1.5 MB
Biçim:
Adobe Portable Document Format